Japanese Clinical Practice Guideline for Head and Neck Cancer

Ken ichi Nibu, Ryuichi Hayashi, Takahiro Asakage, Hiroya Ojiri, Yoshihiro Kimata, Takeshi Kodaira, Toshitaka Nagao, Torahiko Nakashima, Takashi Fujii, Hirofumi Fujii, Akihiro Homma, Kazuto Matsuura, Nobuya Monden, Takeshi Beppu, Nobuhiro Hanai, Tadaaki Kirita, Yuzuru Kamei, Naoki Otsuki, Naomi Kiyota, Sadamoto Zenda & 8 others Ken Omura, Koichi Omori, Tetsuo Akimoto, Kazuyoshi Kawabata, Seiji Kishimoto, Hiroya Kitano, Iwai Tohnai, Takashi Nakatsuka

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Objective The first revision of “Japanese Clinical Practice Guideline for Head and Neck Cancer” was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. Methods 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee. A comprehensive literature search was performed for studies published between 2001 and 2012 using PubMed. Qualified studies were analyzed and the results were evaluated, consolidated and codified by all the committee members. Results Elective neck dissection (ND) does contribute to improvement in survival and should be performed for patients with high-risk tongue cancer. At present, no research has clearly demonstrated the utility of superselective arterial infusion chemotherapy. However, depending on the site and stage of the cancer, combination with radiotherapy may be useful for preserving organ function or improving survival rate. Concurrent CDDP chemotherapy and adjuvant radiotherapy contributes to improvement of survival rate as an adjuvant therapy for advanced squamous cell carcinoma of the head and neck in patients at high risk of recurrence. The anti-EGFR antibody cetuximab (Cmab) has an additive effect with radiotherapy. However, the indication must be carefully considered since this treatment has not been compared with the standard treatment of chemoradiotherapy. Cmab has been shown to have an additive effect with chemotherapy (CDDP/5-FU) in patients with unresectable metastatic or recurrent cancer. Preoperative and postoperative oral care may reduce the risk of postoperative complications such as surgical wound infection and pneumonia in head and neck cancers. Rehabilitation soon after ND for cervical lymph node metastasis is recommended for maintaining and restoring shoulder function. Conclusions In this article, we described most relevant guidelines and CQs for the diagnosis and treatment of head and neck cancer in Japan. These guidelines are not intended to govern therapies that are not shown here, but rather aim to be used as a guide in searching for the most appropriate treatment for individual patient.

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalAuris Nasus Larynx
Volume44
Issue number4
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Head and Neck Neoplasms
Practice Guidelines
Neck Dissection
Drug Therapy
Therapeutics
Japan
Radiotherapy
Survival Rate
Guidelines
Committee Membership
Tongue Neoplasms
Surgical Wound Infection
Adjuvant Radiotherapy
Postoperative Care
Neoplasm Staging
Chemoradiotherapy
PubMed
Fluorouracil
Anti-Idiotypic Antibodies
Neoplasms

Keywords

  • Clinical practice guideline
  • Clinical question
  • Head and neck cancer

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Nibu, K. I., Hayashi, R., Asakage, T., Ojiri, H., Kimata, Y., Kodaira, T., ... Nakatsuka, T. (2017). Japanese Clinical Practice Guideline for Head and Neck Cancer. Auris Nasus Larynx, 44(4), 375-380. https://doi.org/10.1016/j.anl.2017.02.004

Japanese Clinical Practice Guideline for Head and Neck Cancer. / Nibu, Ken ichi; Hayashi, Ryuichi; Asakage, Takahiro; Ojiri, Hiroya; Kimata, Yoshihiro; Kodaira, Takeshi; Nagao, Toshitaka; Nakashima, Torahiko; Fujii, Takashi; Fujii, Hirofumi; Homma, Akihiro; Matsuura, Kazuto; Monden, Nobuya; Beppu, Takeshi; Hanai, Nobuhiro; Kirita, Tadaaki; Kamei, Yuzuru; Otsuki, Naoki; Kiyota, Naomi; Zenda, Sadamoto; Omura, Ken; Omori, Koichi; Akimoto, Tetsuo; Kawabata, Kazuyoshi; Kishimoto, Seiji; Kitano, Hiroya; Tohnai, Iwai; Nakatsuka, Takashi.

In: Auris Nasus Larynx, Vol. 44, No. 4, 01.08.2017, p. 375-380.

Research output: Contribution to journalReview article

Nibu, KI, Hayashi, R, Asakage, T, Ojiri, H, Kimata, Y, Kodaira, T, Nagao, T, Nakashima, T, Fujii, T, Fujii, H, Homma, A, Matsuura, K, Monden, N, Beppu, T, Hanai, N, Kirita, T, Kamei, Y, Otsuki, N, Kiyota, N, Zenda, S, Omura, K, Omori, K, Akimoto, T, Kawabata, K, Kishimoto, S, Kitano, H, Tohnai, I & Nakatsuka, T 2017, 'Japanese Clinical Practice Guideline for Head and Neck Cancer', Auris Nasus Larynx, vol. 44, no. 4, pp. 375-380. https://doi.org/10.1016/j.anl.2017.02.004
Nibu KI, Hayashi R, Asakage T, Ojiri H, Kimata Y, Kodaira T et al. Japanese Clinical Practice Guideline for Head and Neck Cancer. Auris Nasus Larynx. 2017 Aug 1;44(4):375-380. https://doi.org/10.1016/j.anl.2017.02.004
Nibu, Ken ichi ; Hayashi, Ryuichi ; Asakage, Takahiro ; Ojiri, Hiroya ; Kimata, Yoshihiro ; Kodaira, Takeshi ; Nagao, Toshitaka ; Nakashima, Torahiko ; Fujii, Takashi ; Fujii, Hirofumi ; Homma, Akihiro ; Matsuura, Kazuto ; Monden, Nobuya ; Beppu, Takeshi ; Hanai, Nobuhiro ; Kirita, Tadaaki ; Kamei, Yuzuru ; Otsuki, Naoki ; Kiyota, Naomi ; Zenda, Sadamoto ; Omura, Ken ; Omori, Koichi ; Akimoto, Tetsuo ; Kawabata, Kazuyoshi ; Kishimoto, Seiji ; Kitano, Hiroya ; Tohnai, Iwai ; Nakatsuka, Takashi. / Japanese Clinical Practice Guideline for Head and Neck Cancer. In: Auris Nasus Larynx. 2017 ; Vol. 44, No. 4. pp. 375-380.
@article{fdbc0383ea864dcebeedbb90aadedc86,
title = "Japanese Clinical Practice Guideline for Head and Neck Cancer",
abstract = "Objective The first revision of “Japanese Clinical Practice Guideline for Head and Neck Cancer” was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. Methods 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee. A comprehensive literature search was performed for studies published between 2001 and 2012 using PubMed. Qualified studies were analyzed and the results were evaluated, consolidated and codified by all the committee members. Results Elective neck dissection (ND) does contribute to improvement in survival and should be performed for patients with high-risk tongue cancer. At present, no research has clearly demonstrated the utility of superselective arterial infusion chemotherapy. However, depending on the site and stage of the cancer, combination with radiotherapy may be useful for preserving organ function or improving survival rate. Concurrent CDDP chemotherapy and adjuvant radiotherapy contributes to improvement of survival rate as an adjuvant therapy for advanced squamous cell carcinoma of the head and neck in patients at high risk of recurrence. The anti-EGFR antibody cetuximab (Cmab) has an additive effect with radiotherapy. However, the indication must be carefully considered since this treatment has not been compared with the standard treatment of chemoradiotherapy. Cmab has been shown to have an additive effect with chemotherapy (CDDP/5-FU) in patients with unresectable metastatic or recurrent cancer. Preoperative and postoperative oral care may reduce the risk of postoperative complications such as surgical wound infection and pneumonia in head and neck cancers. Rehabilitation soon after ND for cervical lymph node metastasis is recommended for maintaining and restoring shoulder function. Conclusions In this article, we described most relevant guidelines and CQs for the diagnosis and treatment of head and neck cancer in Japan. These guidelines are not intended to govern therapies that are not shown here, but rather aim to be used as a guide in searching for the most appropriate treatment for individual patient.",
keywords = "Clinical practice guideline, Clinical question, Head and neck cancer",
author = "Nibu, {Ken ichi} and Ryuichi Hayashi and Takahiro Asakage and Hiroya Ojiri and Yoshihiro Kimata and Takeshi Kodaira and Toshitaka Nagao and Torahiko Nakashima and Takashi Fujii and Hirofumi Fujii and Akihiro Homma and Kazuto Matsuura and Nobuya Monden and Takeshi Beppu and Nobuhiro Hanai and Tadaaki Kirita and Yuzuru Kamei and Naoki Otsuki and Naomi Kiyota and Sadamoto Zenda and Ken Omura and Koichi Omori and Tetsuo Akimoto and Kazuyoshi Kawabata and Seiji Kishimoto and Hiroya Kitano and Iwai Tohnai and Takashi Nakatsuka",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.anl.2017.02.004",
language = "English",
volume = "44",
pages = "375--380",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Japanese Clinical Practice Guideline for Head and Neck Cancer

AU - Nibu, Ken ichi

AU - Hayashi, Ryuichi

AU - Asakage, Takahiro

AU - Ojiri, Hiroya

AU - Kimata, Yoshihiro

AU - Kodaira, Takeshi

AU - Nagao, Toshitaka

AU - Nakashima, Torahiko

AU - Fujii, Takashi

AU - Fujii, Hirofumi

AU - Homma, Akihiro

AU - Matsuura, Kazuto

AU - Monden, Nobuya

AU - Beppu, Takeshi

AU - Hanai, Nobuhiro

AU - Kirita, Tadaaki

AU - Kamei, Yuzuru

AU - Otsuki, Naoki

AU - Kiyota, Naomi

AU - Zenda, Sadamoto

AU - Omura, Ken

AU - Omori, Koichi

AU - Akimoto, Tetsuo

AU - Kawabata, Kazuyoshi

AU - Kishimoto, Seiji

AU - Kitano, Hiroya

AU - Tohnai, Iwai

AU - Nakatsuka, Takashi

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective The first revision of “Japanese Clinical Practice Guideline for Head and Neck Cancer” was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. Methods 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee. A comprehensive literature search was performed for studies published between 2001 and 2012 using PubMed. Qualified studies were analyzed and the results were evaluated, consolidated and codified by all the committee members. Results Elective neck dissection (ND) does contribute to improvement in survival and should be performed for patients with high-risk tongue cancer. At present, no research has clearly demonstrated the utility of superselective arterial infusion chemotherapy. However, depending on the site and stage of the cancer, combination with radiotherapy may be useful for preserving organ function or improving survival rate. Concurrent CDDP chemotherapy and adjuvant radiotherapy contributes to improvement of survival rate as an adjuvant therapy for advanced squamous cell carcinoma of the head and neck in patients at high risk of recurrence. The anti-EGFR antibody cetuximab (Cmab) has an additive effect with radiotherapy. However, the indication must be carefully considered since this treatment has not been compared with the standard treatment of chemoradiotherapy. Cmab has been shown to have an additive effect with chemotherapy (CDDP/5-FU) in patients with unresectable metastatic or recurrent cancer. Preoperative and postoperative oral care may reduce the risk of postoperative complications such as surgical wound infection and pneumonia in head and neck cancers. Rehabilitation soon after ND for cervical lymph node metastasis is recommended for maintaining and restoring shoulder function. Conclusions In this article, we described most relevant guidelines and CQs for the diagnosis and treatment of head and neck cancer in Japan. These guidelines are not intended to govern therapies that are not shown here, but rather aim to be used as a guide in searching for the most appropriate treatment for individual patient.

AB - Objective The first revision of “Japanese Clinical Practice Guideline for Head and Neck Cancer” was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. Methods 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee. A comprehensive literature search was performed for studies published between 2001 and 2012 using PubMed. Qualified studies were analyzed and the results were evaluated, consolidated and codified by all the committee members. Results Elective neck dissection (ND) does contribute to improvement in survival and should be performed for patients with high-risk tongue cancer. At present, no research has clearly demonstrated the utility of superselective arterial infusion chemotherapy. However, depending on the site and stage of the cancer, combination with radiotherapy may be useful for preserving organ function or improving survival rate. Concurrent CDDP chemotherapy and adjuvant radiotherapy contributes to improvement of survival rate as an adjuvant therapy for advanced squamous cell carcinoma of the head and neck in patients at high risk of recurrence. The anti-EGFR antibody cetuximab (Cmab) has an additive effect with radiotherapy. However, the indication must be carefully considered since this treatment has not been compared with the standard treatment of chemoradiotherapy. Cmab has been shown to have an additive effect with chemotherapy (CDDP/5-FU) in patients with unresectable metastatic or recurrent cancer. Preoperative and postoperative oral care may reduce the risk of postoperative complications such as surgical wound infection and pneumonia in head and neck cancers. Rehabilitation soon after ND for cervical lymph node metastasis is recommended for maintaining and restoring shoulder function. Conclusions In this article, we described most relevant guidelines and CQs for the diagnosis and treatment of head and neck cancer in Japan. These guidelines are not intended to govern therapies that are not shown here, but rather aim to be used as a guide in searching for the most appropriate treatment for individual patient.

KW - Clinical practice guideline

KW - Clinical question

KW - Head and neck cancer

UR - http://www.scopus.com/inward/record.url?scp=85015442942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015442942&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2017.02.004

DO - 10.1016/j.anl.2017.02.004

M3 - Review article

VL - 44

SP - 375

EP - 380

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 4

ER -